Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model

Pharmacological activation of group III metabotropic glutamate receptors (mGluR) or inhibition of group I mGluR by subtype-selective ligands is neuroprotective in experimental models of Parkinson's disease. The aim of this study was to investigate whether targeting both receptor subtypes simultaneously produces enhanced neuroprotection. Rodents bearing a 6-hydroxydopamine lesion were intranigrally administered either the group III mGluR agonist L-(+)-2-amino-4-phosphonobutyric acid or the group I mGluR antagonist 2-methyl-6-(phenylethynyl)pyridine, alone or in combination. Coadministration of L-(+)-2-amino-4-phosphonobutyric acid and 2-methyl-6-(phenylethynyl)pyridine resulted in robust nigrostriatal neuroprotection that was significantly increased compared with either compound alone. These data suggest that targeting multiple mGluR subtypes with low doses of selective ligands may provide an enhanced therapeutic response in experimental models of Parkinson's disease.

[1]  Fred H. Gage,et al.  Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior , 1991, Brain Research.

[2]  M. Croucher,et al.  Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6‐hydroxydopamine toxicity in vivo , 2007, Journal of neurochemistry.

[3]  D. Dexter,et al.  Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions , 2001, Movement disorders : official journal of the Movement Disorder Society.

[4]  K. Fuxe,et al.  Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP , 2005, Brain Research.

[5]  M. Croucher,et al.  Selective Activation of Group Iii Metabotropic Glutamate Receptors by L-(+)-2-amino-4- Phosphonobutryic Acid Protects the Nigrostriatal System against 6-hydroxydopamine Toxicity in Vivo Running Title Section: Neuropharmacology Group Iii Mglur Activation Neuroprotective against 6-ohda , 2022 .

[6]  Deanna L. Taylor,et al.  Stimulation of Microglial Metabotropic Glutamate Receptor mGlu2 Triggers Tumor Necrosis Factor α-Induced Neurotoxicity in Concert with Microglial-Derived Fas Ligand , 2005, The Journal of Neuroscience.

[7]  Kazuto Kobayashi,et al.  Granulocyte‐colony stimulating factor is neuroprotective in a model of Parkinson's disease , 2006, Journal of neurochemistry.

[8]  M. G. Lacey,et al.  Metabotropic glutamate receptors depress glutamate‐mediated synaptic input to rat midbrain dopamine neurones in vitro , 1998, British journal of pharmacology.

[9]  M. Horne,et al.  Timecourse of striatal re‐innervation following lesions of dopaminergic SNpc neurons of the rat , 2003, The European journal of neuroscience.

[10]  P. Conn,et al.  Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.

[11]  Y. Smith,et al.  Differential Subcellular Localization of mGluR1a and mGluR5 in the Rat and Monkey Substantia Nigra , 2001, The Journal of Neuroscience.

[12]  G. Hu,et al.  Activation of Group II/III metabotropic glutamate receptors attenuates LPS‐induced astroglial neurotoxicity via promoting glutamate uptake , 2006, Journal of neuroscience research.

[13]  W. Danysz,et al.  The role of excitotoxicity in neurodegeneration. , 2006, Folia neuropathologica.

[14]  P. Conn,et al.  Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. , 2000, Pharmacology & therapeutics.

[15]  F. Nicoletti,et al.  The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection , 2007, The Journal of Neuroscience.

[16]  J. M. Mathiesen,et al.  Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB‐1893 and MPEP , 2003, British journal of pharmacology.

[17]  P. Conn,et al.  Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. , 2006, Current opinion in pharmacology.

[18]  F. Nicoletti,et al.  Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.

[19]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.